Recent Advances for Targeted Therapies in Glioblastoma

  • Michael Youssef
  • Jacob Mandel
  • Sajeel Chowdhary
  • Santosh Kesari
Chapter
First Online:
Part of the Current Cancer Research book series (CUCR)

Abstract

Glioblastoma (GBM) is the most common primary brain tumors in adults. Despite aggressive multimodality therapies, GBM unfortunately remains among the most resistant cancers to treatment. In the past, traditional chemotherapy which works by impeding DNA synthesis or cell metabolism has been used to try and slow the progression of GBM with little success. Recently, research has become more focused into the development of targeted therapies in which drugs (small molecules or antibodies) effect specific molecular and genetic alterations in GBM attempting to inhibit and deregulate cell signaling pathways. The Cancer Genome Atlas (TCGA) GBM project has provided an in depth description of the distinct molecular and genetic alterations in GBM stimulating interest in the development of targeted molecular therapies. While the results of targeted therapy studies to date have failed to improve the overall survival of GBM patients, there continues to be enthusiasm in this approach with numerous clinical trials currently underway. Hopefully, knowledge from the previous failed trials will help provide further insight and assist future clinicians in designing new novel targeted treatments to overcome these barriers.

Keywords

Glioblastoma targeted therapy The Cancer Genome Atlas Retinoblastoma pathway p53 pathway Receptor tyrosine kinase pathway 
This is a preview of subscription content, log in to check access.

References

  1. Akhavan, D., T.F. Cloughesy, and P.S. Mischel. 2010. mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro-Oncology 12: 882–889.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Alcantara Llaguno, S., J. Chen, C.H. Kwon, et al. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15: 45–56.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Alentorn, A., Y. Marie, C. Carpentier, et al. 2012. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. Neuro-Oncology 14: 1393–1403.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Banerjee, S., N.R. Crouse, R.J. Emnett, S.M. Gianino, and D.H. Gutmann. 2011. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proceedings of the National Academy of Sciences of the United States of America 108: 15996–16001.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bastien, J.I., K.A. McNeill, and H.A. Fine. 2015. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121: 502–516.PubMedCrossRefGoogle Scholar
  6. Batchelor, T.T., D.G. Duda, E. di Tomaso, et al. 2010. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of Clinical Oncology 28: 2817–2823.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Batchelor, T.T., P. Mulholland, B. Neyns, et al. 2013. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of Clinical Oncology 31: 3212–3218.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Baysan, M., S. Bozdag, M.C. Cam, et al. 2012. G-cimp status prediction of glioblastoma samples using mRNA expression data. PLoS One 7: e47839.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bello, M.J., J. Vaquero, J.M. de Campos, et al. 1994. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. International Journal of Cancer 57: 172–175.PubMedCrossRefGoogle Scholar
  10. Bianco, R., I. Shin, C.A. Ritter, et al. 2003. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812–2822.PubMedCrossRefGoogle Scholar
  11. Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411: 355–365.PubMedCrossRefGoogle Scholar
  12. Bogler, O., H.J. Huang, P. Kleihues, and W.K. Cavenee. 1995. The p53 gene and its role in human brain tumors. Glia 15: 308–327.PubMedCrossRefGoogle Scholar
  13. Brandes, A.A., R. Stupp, P. Hau, et al. 2010. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. European Journal of Cancer 46: 348–354.PubMedCrossRefGoogle Scholar
  14. Bredel, M., D.M. Scholtens, A.K. Yadav, et al. 2011. NFKBIA deletion in glioblastomas. The New England Journal of Medicine 364: 627–637.PubMedCrossRefGoogle Scholar
  15. Brennan, C.W., R.G. Verhaak, A. McKenna, et al. 2013. The somatic genomic landscape of glioblastoma. Cell 155: 462–477.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Brown, P.D., S. Krishnan, J.N. Sarkaria, et al. 2008. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology 26: 5603–5609.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Buchdunger, E., C.L. Cioffi, N. Law, et al. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. The Journal of Pharmacology and Experimental Therapeutics 295: 139–145.PubMedGoogle Scholar
  18. Butowski, N., S.M. Chang, K.R. Lamborn, et al. 2011. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro-Oncology 13: 1331–1338.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068.CrossRefGoogle Scholar
  20. Carnero, A., C. Blanco-Aparicio, O. Renner, W. Link, and J.F. Leal. 2008. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current Cancer Drug Targets 8: 187–198.PubMedCrossRefGoogle Scholar
  21. Chakravarti, A., J.S. Loeffler, and N.J. Dyson. 2002. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Research 62: 200–207.PubMedGoogle Scholar
  22. Chakravarti, A., M. Wang, H.I. Robins, et al. 2013. RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. International Journal of Radiation Oncology, Biology, Physics 85: 1206–1211.PubMedCrossRefGoogle Scholar
  23. Chang, S.M., P. Wen, T. Cloughesy, et al. 2005. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs 23: 357–361.PubMedCrossRefGoogle Scholar
  24. Chheda, M.G., P.Y. Wen, F.H. Hochberg, et al. 2015. Vandetanib plus sirolimus in adults with recurrent glioblastoma: Results of a phase I and dose expansion cohort study. Journal of Neuro-Oncology 121: 627–634.PubMedCrossRefGoogle Scholar
  25. Chinot, O.L., W. Wick, W. Mason, et al. 2014. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine 370: 709–722.PubMedCrossRefGoogle Scholar
  26. ClinicalTrialsgov. 2016. Bevacizumab and Lomustine for Recurrent GBM. Identifier: NCT01290939.Google Scholar
  27. Cloughesy, T.F., P.Y. Wen, H.I. Robins, et al. 2006. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology 24: 3651–3656.PubMedCrossRefGoogle Scholar
  28. Cloughesy, T.R.J., J. Drappatz, et al. 2011. A phase II trial of everolimus in patients with recurrent glioblastoma multiforme. Neuro-Oncology 13: 42–43.CrossRefGoogle Scholar
  29. Cloughesy, T.F., W.K. Cavenee, and P.S. Mischel. 2014. Glioblastoma: From molecular pathology to targeted treatment. Annual Review of Pathology 9: 1–25.PubMedCrossRefGoogle Scholar
  30. Cohen, M.H., Y.L. Shen, P. Keegan, and R. Pazdur. 2009. FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. The Oncologist 14: 1131–1138.PubMedCrossRefGoogle Scholar
  31. Dang, L., S. Jin, and S.M. Su. 2010. IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine 16: 387–397.PubMedCrossRefGoogle Scholar
  32. Dasgupta, B., W. Li, A. Perry, and D.H. Gutmann. 2005. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Research 65: 236–245.PubMedGoogle Scholar
  33. Davis, F.G., V. Kupelian, S. Freels, B. McCarthy, and T. Surawicz. 2001. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology 3: 152–158.PubMedPubMedCentralGoogle Scholar
  34. de Groot, J.F., M.R. Gilbert, K. Aldape, et al. 2008. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. Journal of Neuro-Oncology 90: 89–97.PubMedCrossRefGoogle Scholar
  35. de Groot, J.F., K.R. Lamborn, S.M. Chang, et al. 2011. Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. Journal of Clinical Oncology 29: 2689–2695.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Demetri, G.D., M. von Mehren, C.D. Blanke, et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine 347: 472–480.PubMedCrossRefGoogle Scholar
  37. Desjardins, A., J.A. Quinn, J.J. Vredenburgh, et al. 2007. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology 83: 53–60.PubMedCrossRefGoogle Scholar
  38. Desjardins, A., D.A. Reardon, K.B. Peters, et al. 2011. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. Journal of Neuro-Oncology 105: 601–606.PubMedCrossRefGoogle Scholar
  39. Dresemann, G., M. Weller, M.A. Rosenthal, et al. 2010. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology 96: 393–402.PubMedCrossRefGoogle Scholar
  40. Druker, B.J., M. Talpaz, D.J. Resta, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine 344: 1031–1037.PubMedCrossRefGoogle Scholar
  41. Facchinetti, V., W. Ouyang, H. Wei, et al. 2008. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. The EMBO Journal 27: 1932–1943.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Fan, Q.W., C. Cheng, C. Hackett, et al. 2010. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Science Signaling 3: ra81.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Ferrara, N., K.J. Hillan, and W. Novotny. 2005. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications 333: 328–335.PubMedCrossRefGoogle Scholar
  44. Field, K.M., J. Simes, A.K. Nowak, et al. 2015. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-Oncology 17: 1504–1513.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Franceschi, E., G. Cavallo, S. Lonardi, et al. 2007. Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer 96: 1047–1051.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Franceschi, E., R. Stupp, M.J. van den Bent, et al. 2012. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro-Oncology 14: 1503–1510.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Freije, W.A., F.E. Castro-Vargas, Z. Fang, et al. 2004. Gene expression profiling of gliomas strongly predicts survival. Cancer Research 64: 6503–6510.PubMedCrossRefGoogle Scholar
  48. Friedman, H.S., M.D. Prados, P.Y. Wen, et al. 2009. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology 27: 4733–4740.PubMedCrossRefGoogle Scholar
  49. Galanis, E., J.C. Buckner, M.J. Maurer, et al. 2005. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology 23: 5294–5304.PubMedCrossRefGoogle Scholar
  50. Galanis, E., S.K. Anderson, J.M. Lafky, et al. 2013. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): A north central cancer treatment group trial. Clinical Cancer Research 19: 4816–4823.PubMedCrossRefGoogle Scholar
  51. Gan, H.K., A.H. Kaye, and R.B. Luwor. 2009. The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience 16: 748–754.PubMedCrossRefGoogle Scholar
  52. Gan, H.K., P. Kumthekar, A.B. Lassman, et al. 2015. ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY. Neuro-Oncology 17: v10.CrossRefGoogle Scholar
  53. Gerstner, E.R., A.F. Eichler, S.R. Plotkin, et al. 2011. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. Journal of Neuro-Oncology 103: 325–332.PubMedCrossRefGoogle Scholar
  54. Gilbert, M.R., J.J. Dignam, T.S. Armstrong, et al. 2014. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine 370: 699–708.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Gravendeel, L.A., M.C. Kouwenhoven, O. Gevaert, et al. 2009. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Research 69: 9065–9072.PubMedCrossRefGoogle Scholar
  56. Gross, S., R.A. Cairns, M.D. Minden, et al. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. The Journal of Experimental Medicine 207: 339–344.PubMedPubMedCentralCrossRefGoogle Scholar
  57. Haas-Kogan, D.A., M.D. Prados, T. Tihan, et al. 2005. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. Journal of the National Cancer Institute 97: 880–887.PubMedCrossRefGoogle Scholar
  58. Hainsworth, J.D., T. Ervin, E. Friedman, et al. 2010. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116: 3663–3669.PubMedCrossRefGoogle Scholar
  59. Hainsworth, J.D., K.C. Shih, G.C. Shepard, G.W. Tillinghast, B.T. Brinker, and D.R. Spigel. 2012. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clinical Advances in Hematology & Oncology 10: 240–246.Google Scholar
  60. Hartmann, C., J. Meyer, J. Balss, et al. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica 118: 469–474.PubMedCrossRefGoogle Scholar
  61. Hasselbalch, B., U. Lassen, S. Hansen, et al. 2010. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. Neuro-Oncology 12: 508–516.PubMedPubMedCentralGoogle Scholar
  62. Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes & Development 18: 1926–1945.CrossRefGoogle Scholar
  63. Hegi, M.E., A.C. Diserens, P. Bady, et al. 2011. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib – A phase II trial. Molecular Cancer Therapeutics 10: 1102–1112.PubMedCrossRefGoogle Scholar
  64. Herman, A.G., M. Hayano, M.V. Poyurovsky, et al. 2011. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discovery 1: 312–325.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Huang, P.H., A. Mukasa, R. Bonavia, et al. 2007. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 104: 12867–12872.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Ikenoue, T., K. Inoki, Q. Yang, X. Zhou, and K.L. Guan. 2008. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. The EMBO Journal 27: 1919–1931.PubMedPubMedCentralCrossRefGoogle Scholar
  67. Inman S. 2016. Rindopepimut misses OS endpoint in phase III glioblastoma trial. OncLive. http://www.onclive.com/web-exclusives/rindopepimut-misses-os-endpoint-in-phase-iii-glioblastoma-trial.
  68. Iwamoto, F.M., K.R. Lamborn, H.I. Robins, et al. 2010. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology 12: 855–861.PubMedPubMedCentralCrossRefGoogle Scholar
  69. James, C.D., J. He, E. Carlbom, M. Nordenskjold, W.K. Cavenee, and V.P. Collins. 1991. Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Research 51: 1684–1688.PubMedGoogle Scholar
  70. Jaros, E., R.H. Perry, L. Adam, et al. 1992. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. British Journal of Cancer 66: 373–385.PubMedPubMedCentralCrossRefGoogle Scholar
  71. Jo, M., D.B. Stolz, J.E. Esplen, K. Dorko, G.K. Michalopoulos, and S.C. Strom. 2000. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. The Journal of Biological Chemistry 275: 8806–8811.PubMedCrossRefGoogle Scholar
  72. Jue, T.R., and K.L. McDonald. 2016. The challenges associated with molecular targeted therapies for glioblastoma. Journal of Neuro-Oncology 127: 427–434.PubMedCrossRefGoogle Scholar
  73. Kamijo, T., F. Zindy, M.F. Roussel, et al. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649–659.PubMedCrossRefGoogle Scholar
  74. Kamijo, T., J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proceedings of the National Academy of Sciences of the United States of America 95: 8292–8297.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Karavasilis, V., V. Kotoula, G. Pentheroudakis, et al. 2013. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. Journal of Neurology 260: 1469–1480.PubMedCrossRefGoogle Scholar
  76. Kim, D.H., D.D. Sarbassov, S.M. Ali, et al. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163–175.PubMedCrossRefGoogle Scholar
  77. Kong, D.S., S.Y. Song, D.H. Kim, et al. 2009. Prognostic significance of c-Met expression in glioblastomas. Cancer 115: 140–148.PubMedCrossRefGoogle Scholar
  78. Koochekpour, S., M. Jeffers, S. Rulong, et al. 1997. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Research 57: 5391–5398.PubMedGoogle Scholar
  79. Koul, D. 2008. PTEN signaling pathways in glioblastoma. Cancer Biology & Therapy 7: 1321–1325.CrossRefGoogle Scholar
  80. Kreisl, T.N., L. Kim, K. Moore, et al. 2009a. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 27: 740–745.PubMedCrossRefGoogle Scholar
  81. Kreisl, T.N., A.B. Lassman, P.S. Mischel, et al. 2009b. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of Neuro-Oncology 92: 99–105.PubMedCrossRefGoogle Scholar
  82. Kreisl, T.N., S. Kotliarova, J.A. Butman, et al. 2010. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology 12: 181–189.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Kreisl, T.N., K.A. McNeill, J. Sul, F.M. Iwamoto, J. Shih, and H.A. Fine. 2012. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro-Oncology 14: 1519–1526.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Kreisl, T.N., P. Smith, J. Sul, et al. 2013. Continuous daily sunitinib for recurrent glioblastoma. Journal of Neuro-Oncology 111: 41–48.PubMedCrossRefGoogle Scholar
  85. Krishnan, S., P.D. Brown, K.V. Ballman, et al. 2006. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. International Journal of Radiation Oncology, Biology, Physics 65: 1192–1199.PubMedCrossRefGoogle Scholar
  86. Kruser, T.J., M.P. Mehta, and K.R. Kozak. 2016. Identification of patients who benefit from bevacizumab in high-grade glioma-an easy question turned difficult: Treat the scan or the patient? Journal of Clinical Oncology 34: 1281–1282.PubMedCrossRefGoogle Scholar
  87. Kwon, C.H., D. Zhao, J. Chen, et al. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Research 68: 3286–3294.PubMedPubMedCentralCrossRefGoogle Scholar
  88. Lamszus, K., J. Laterra, M. Westphal, and E.M. Rosen. 1999. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. International Journal of Developmental Neuroscience 17: 517–530.PubMedCrossRefGoogle Scholar
  89. Lassen, U., M. Sorensen, T.B. Gaziel, B. Hasselbalch, and H.S. Poulsen. 2013. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Research 33: 1657–1660.PubMedGoogle Scholar
  90. Lassman, A.B., S.L. Pugh, M.R. Gilbert, et al. 2015. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology 17: 992–998.PubMedCrossRefGoogle Scholar
  91. Lee, E.Q., J. Kuhn, K.R. Lamborn, et al. 2012. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology 14: 1511–1518.PubMedPubMedCentralCrossRefGoogle Scholar
  92. Li, J., C. Yen, D. Liaw, et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.PubMedCrossRefGoogle Scholar
  93. Li, A., J. Walling, S. Ahn, et al. 2009. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Research 69: 2091–2099.PubMedPubMedCentralCrossRefGoogle Scholar
  94. Lin, F., M.C. de Gooijer, D. Hanekamp, D. Brandsma, J.H. Beijnen, and O. van Tellingen. 2013. Targeting core (mutated) pathways of high-grade gliomas: Challenges of intrinsic resistance and drug efflux. CNS Oncology 2: 271–288.PubMedCrossRefGoogle Scholar
  95. Liu, W., C.D. James, L. Frederick, B.E. Alderete, and R.B. Jenkins. 1997. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Research 57: 5254–5257.PubMedGoogle Scholar
  96. Loenarz, C., and C.J. Schofield. 2008. Expanding chemical biology of 2-oxoglutarate oxygenases. Nature Chemical Biology 4: 152–156.PubMedCrossRefGoogle Scholar
  97. Louis, D.N., A. Perry, G. Reifenberger, et al. 2016. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathologica 131: 803–820.PubMedCrossRefGoogle Scholar
  98. Ma, D.J., E. Galanis, S.K. Anderson, et al. 2015. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology 17: 1261–1269.PubMedCrossRefGoogle Scholar
  99. Mandel, J.J., D. Cachia, D. Liu, et al. 2016. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. Journal of Neuro-Oncology 129: 147–154.PubMedCrossRefGoogle Scholar
  100. Mao, H., D.G. Lebrun, J. Yang, V.F. Zhu, and M. Li. 2012. Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets. Cancer Investigation 30: 48–56.PubMedPubMedCentralCrossRefGoogle Scholar
  101. Masui, K., T.F. Cloughesy, and P.S. Mischel. 2012. Review: Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology 38: 271–291.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Matlashewski, G., P. Lamb, D. Pim, J. Peacock, L. Crawford, and S. Benchimol. 1984. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. The EMBO Journal 3: 3257–3262.PubMedPubMedCentralGoogle Scholar
  103. Matsui, T., M. Heidaran, T. Miki, et al. 1989. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 243: 800–804.PubMedCrossRefGoogle Scholar
  104. May, P., and E. May. 1999. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 18: 7621–7636.PubMedCrossRefGoogle Scholar
  105. McGillicuddy, L.T., J.A. Fromm, P.E. Hollstein, et al. 2009. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16: 44–54.PubMedPubMedCentralCrossRefGoogle Scholar
  106. Mellinghoff, I.K., M.Y. Wang, I. Vivanco, et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine 353: 2012–2024.PubMedCrossRefGoogle Scholar
  107. Moodie, S.A., B.M. Willumsen, M.J. Weber, and A. Wolfman. 1993. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260: 1658–1661.PubMedCrossRefGoogle Scholar
  108. Morgensztern, D., and H.L. McLeod. 2005. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 16: 797–803.PubMedCrossRefGoogle Scholar
  109. Muhic, A., H.S. Poulsen, M. Sorensen, K. Grunnet, and U. Lassen. 2013. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 111: 205–212.PubMedCrossRefGoogle Scholar
  110. Mukherjee, B., N. Tomimatsu, K. Amancherla, C.V. Camacho, N. Pichamoorthy, and S. Burma. 2012. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14: 34–43.PubMedPubMedCentralCrossRefGoogle Scholar
  111. Murphree, A.L., and W.F. Benedict. 1984. Retinoblastoma: Clues to human oncogenesis. Science 223: 1028–1033.PubMedCrossRefGoogle Scholar
  112. Neyns, B., J. Sadones, E. Joosens, et al. 2009. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Annals of Oncology 20: 1596–1603.PubMedCrossRefGoogle Scholar
  113. Neyns, B., J. Sadones, C. Chaskis, et al. 2011. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 103: 491–501.PubMedCrossRefGoogle Scholar
  114. Nghiemphu, P.L., P.Y. Wen, K.R. Lamborn, et al. 2011. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics 81: 1422–1427.PubMedCrossRefGoogle Scholar
  115. Nghiemphu, P.L., A. Lai, R.M. Green, D.A. Reardon, and T. Cloughesy. 2012. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. Journal of Neuro-Oncology 110: 245–250.PubMedPubMedCentralCrossRefGoogle Scholar
  116. Nigro, J.M., A. Misra, L. Zhang, et al. 2005. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Research 65: 1678–1686.PubMedCrossRefGoogle Scholar
  117. Nishikawa, R., X.D. Ji, R.C. Harmon, et al. 1994. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America 91: 7727–7731.PubMedPubMedCentralCrossRefGoogle Scholar
  118. Nishikawa, R., T. Sugiyama, Y. Narita, F. Furnari, W.K. Cavenee, and M. Matsutani. 2004. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathology 21: 53–56.PubMedCrossRefGoogle Scholar
  119. Nissan, M.H., C.A. Pratilas, A.M. Jones, et al. 2014. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Research 74: 2340–2350.PubMedPubMedCentralCrossRefGoogle Scholar
  120. Noushmehr, H., D.J. Weisenberger, K. Diefes, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510–522.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Ohgaki, H., and P. Kleihues. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Journal of Neuropathology and Experimental Neurology 64: 479–489.PubMedCrossRefGoogle Scholar
  122. ———. 2009. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science 100: 2235–2241.PubMedCrossRefGoogle Scholar
  123. Pan, E., D. Yu, B. Yue, et al. 2012. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. Journal of Neuro-Oncology 110: 111–118.PubMedCrossRefGoogle Scholar
  124. Parsons, D.W., S. Jones, X. Zhang, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.PubMedPubMedCentralCrossRefGoogle Scholar
  125. Peereboom, D.M., D.R. Shepard, M.S. Ahluwalia, et al. 2010. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of Neuro-Oncology 98: 93–99.PubMedCrossRefGoogle Scholar
  126. Peereboom, D.M., M.S. Ahluwalia, X. Ye, et al. 2013. NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-Oncology 15: 490–496.PubMedPubMedCentralCrossRefGoogle Scholar
  127. Peraud, A., K. Watanabe, K.H. Plate, Y. Yonekawa, P. Kleihues, and H. Ohgaki. 1997. p53 mutations versus EGF receptor expression in giant cell glioblastomas. Journal of Neuropathology and Experimental Neurology 56: 1236–1241.PubMedCrossRefGoogle Scholar
  128. Phillips, H.S., S. Kharbanda, R. Chen, et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157–173.PubMedCrossRefGoogle Scholar
  129. Phillips, A.C., E.R. Boghaert, K.S. Vaidya, et al. 2016. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Molecular Cancer Therapeutics 15: 661–669.PubMedCrossRefGoogle Scholar
  130. Porter, K.R., B.J. McCarthy, S. Freels, Y. Kim, and F.G. Davis. 2010. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncology 12: 520–527.PubMedPubMedCentralCrossRefGoogle Scholar
  131. Prados, M.D., K.R. Lamborn, S. Chang, et al. 2006. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-Oncology 8: 67–78.PubMedPubMedCentralCrossRefGoogle Scholar
  132. Prados, M.D., S.M. Chang, N. Butowski, et al. 2009. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Journal of Clinical Oncology 27: 579–584.PubMedCrossRefGoogle Scholar
  133. Prados, M.D., S.A. Byron, N.L. Tran, et al. 2015. Toward precision medicine in glioblastoma: The promise and the challenges. Neuro-Oncology 17: 1051–1063.PubMedPubMedCentralCrossRefGoogle Scholar
  134. Purow, B., and D. Schiff. 2009. Advances in the genetics of glioblastoma: Are we reaching critical mass? Nature Reviews. Neurology 5: 419–426.PubMedPubMedCentralCrossRefGoogle Scholar
  135. Raizer, J.J., L.E. Abrey, A.B. Lassman, et al. 2010. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology 12: 95–103.PubMedCrossRefGoogle Scholar
  136. Razis, E., P. Selviaridis, S. Labropoulos, et al. 2009. Phase II study of neoadjuvant imatinib in glioblastoma: Evaluation of clinical and molecular effects of the treatment. Clinical Cancer Research 15: 6258–6266.PubMedCrossRefGoogle Scholar
  137. Reardon, D.A., M.J. Egorin, J.A. Quinn, et al. 2005. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology 23: 9359–9368.PubMedCrossRefGoogle Scholar
  138. Reardon, D.A., J.A. Quinn, J.J. Vredenburgh, et al. 2006. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research 12: 860–868.PubMedCrossRefGoogle Scholar
  139. Reardon, D.A., G. Dresemann, S. Taillibert, et al. 2009a. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British Journal of Cancer 101: 1995–2004.PubMedPubMedCentralCrossRefGoogle Scholar
  140. Reardon, D.A., M.J. Egorin, A. Desjardins, et al. 2009b. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115: 2188–2198.PubMedPubMedCentralCrossRefGoogle Scholar
  141. Reardon, D.A., A. Desjardins, J.J. Vredenburgh, et al. 2010. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology 96: 219–230.PubMedCrossRefGoogle Scholar
  142. Reardon, D.A., J.J. Vredenburgh, A. Desjardins, et al. 2011a. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology 101: 57–66.PubMedCrossRefGoogle Scholar
  143. Reardon, D.A., J.J. Vredenburgh, A. Coan, et al. 2011b. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. Journal of Neuro-Oncology 105: 621–627.PubMedPubMedCentralCrossRefGoogle Scholar
  144. Reardon, D.A., J.J. Vredenburgh, A. Desjardins, et al. 2012. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology 108: 499–506.PubMedPubMedCentralCrossRefGoogle Scholar
  145. Reardon, D.A., M.D. Groves, P.Y. Wen, et al. 2013. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical Cancer Research 19: 900–908.PubMedCrossRefGoogle Scholar
  146. Reardon, D.A., P.Y. Wen, and I.K. Mellinghoff. 2014. Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-Oncology 16 Suppl 8: viii7–vii13.PubMedCrossRefGoogle Scholar
  147. Reardon, D.A., A. Desjardins, J. Schuster, et al. 2015. IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. Neuro-Oncology 17: v109.PubMedCentralGoogle Scholar
  148. Reifenberger, G., L. Liu, K. Ichimura, E.E. Schmidt, and V.P. Collins. 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Research 53: 2736–2739.PubMedGoogle Scholar
  149. Reifenberger, G., J. Reifenberger, K. Ichimura, and V.P. Collins. 1995. Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Research 55: 731–734.PubMedGoogle Scholar
  150. Rey, J.A., M.J. Bello, J.M. de Campos, M.E. Kusak, C. Ramos, and J. Benitez. 1987. Chromosomal patterns in human malignant astrocytomas. Cancer Genetics and Cytogenetics 29: 201–221.PubMedCrossRefGoogle Scholar
  151. Rich, J.N., D.A. Reardon, T. Peery, et al. 2004. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology 22: 133–142.PubMedCrossRefGoogle Scholar
  152. Riemenschneider, M.J., R. Buschges, M. Wolter, et al. 1999. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Research 59: 6091–6096.PubMedGoogle Scholar
  153. Ruas, M., and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochimica et Biophysica Acta 1378: F115–F177.PubMedGoogle Scholar
  154. Sami, A., and M. Karsy. 2013. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: Novel therapeutic agents and advances in understanding. Tumour Biology 34: 1991–2002.PubMedCrossRefGoogle Scholar
  155. Sandmann, T., R. Bourgon, J. Garcia, et al. 2015. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: Retrospective analysis of the AVAglio trial. Journal of Clinical Oncology 33: 2735–2744.PubMedPubMedCentralCrossRefGoogle Scholar
  156. Sanson, M., Y. Marie, S. Paris, et al. 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology 27: 4150–4154.PubMedCrossRefGoogle Scholar
  157. Sarbassov, D.D., S.M. Ali, D.H. Kim, et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology 14: 1296–1302.PubMedCrossRefGoogle Scholar
  158. Sarbassov, D.D., D.A. Guertin, S.M. Ali, and D.M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.PubMedCrossRefGoogle Scholar
  159. Sarkaria, J.N., E. Galanis, W. Wu, et al. 2010. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clinical Cancer Research 16: 5573–5580.PubMedPubMedCentralCrossRefGoogle Scholar
  160. Sathornsumetee, S., A. Desjardins, J.J. Vredenburgh, et al. 2010. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology 12: 1300–1310.PubMedPubMedCentralCrossRefGoogle Scholar
  161. Schlegel, J., G. Stumm, K. Brandle, et al. 1994. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. Journal of Neuro-Oncology 22: 201–207.PubMedCrossRefGoogle Scholar
  162. Schmidt, E.E., K. Ichimura, G. Reifenberger, and V.P. Collins. 1994. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Research 54: 6321–6324.PubMedGoogle Scholar
  163. See, W.L., I.L. Tan, J. Mukherjee, T. Nicolaides, and R.O. Pieper. 2012. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Research 72: 3350–3359.PubMedPubMedCentralCrossRefGoogle Scholar
  164. Soffietti, R., E. Trevisan, L. Bertero, et al. 2014. Bevacizumab and fotemustine for recurrent glioblastoma: A phase II study of AINO (Italian Association of Neuro-Oncology). Journal of Neuro-Oncology 116: 533–541.PubMedCrossRefGoogle Scholar
  165. Solomon, M.T., J.C. Selva, J. Figueredo, et al. 2013. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: Results from a randomized, double blind trial. BMC Cancer 13: 299.PubMedPubMedCentralCrossRefGoogle Scholar
  166. Stambolic, V., A. Suzuki, J.L. de la Pompa, et al. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29–39.PubMedCrossRefGoogle Scholar
  167. Stenman, G., F. Rorsman, K. Huebner, and C. Betsholtz. 1992. The human platelet-derived growth factor alpha chain (PDGFA) gene maps to chromosome 7p22. Cytogenetics and Cell Genetics 60: 206–207.PubMedCrossRefGoogle Scholar
  168. Stommel, J.M., A.C. Kimmelman, H. Ying, et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287–290.PubMedCrossRefGoogle Scholar
  169. Stupp, R., W.P. Mason, M.J. van den Bent, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 352: 987–996.PubMedCrossRefGoogle Scholar
  170. Sunayama, J., A. Sato, K. Matsuda, et al. 2010. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro-Oncology 12: 1205–1219.PubMedPubMedCentralCrossRefGoogle Scholar
  171. Swartz, A.M., Q.J. Li, and J.H. Sampson. 2014. Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy 6: 679–690.PubMedPubMedCentralCrossRefGoogle Scholar
  172. Taal, W., H.M. Oosterkamp, A.M. Walenkamp, et al. 2014. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. The Lancet Oncology 15: 943–953.PubMedCrossRefGoogle Scholar
  173. Tanaka, S., D.N. Louis, W.T. Curry, T.T. Batchelor, and J. Dietrich. 2013. Diagnostic and therapeutic avenues for glioblastoma: No longer a dead end? Nature Reviews. Clinical Oncology 10: 14–26.PubMedCrossRefGoogle Scholar
  174. Teng, D.H., R. Hu, H. Lin, et al. 1997. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Research 57: 5221–5225.PubMedGoogle Scholar
  175. Thiessen, B., C. Stewart, M. Tsao, et al. 2010. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology 65: 353–361.PubMedCrossRefGoogle Scholar
  176. Thomas, S.M., M. DeMarco, G. D’Arcangelo, S. Halegoua, and J.S. Brugge. 1992. Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell 68: 1031–1040.PubMedCrossRefGoogle Scholar
  177. Tohma, Y., C. Gratas, W. Biernat, et al. 1998. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Journal of Neuropathology and Experimental Neurology 57: 684–689.PubMedCrossRefGoogle Scholar
  178. Uhm, J.H., K.V. Ballman, W. Wu, et al. 2011. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology, Biology, Physics 80: 347–353.PubMedCrossRefGoogle Scholar
  179. van den Bent, M.J., Y. Gao, M. Kerkhof, et al. 2015. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology 17: 935–941.PubMedCrossRefGoogle Scholar
  180. Verhaak, R.G., K.A. Hoadley, E. Purdom, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98–110.PubMedPubMedCentralCrossRefGoogle Scholar
  181. Vitucci, M., D.N. Hayes, and C.R. Miller. 2011. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. British Journal of Cancer 104: 545–553.PubMedCrossRefGoogle Scholar
  182. Vivanco, I., D. Rohle, M. Versele, et al. 2010. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America 107: 6459–6464.PubMedPubMedCentralCrossRefGoogle Scholar
  183. Wang, S.I., J. Puc, J. Li, et al. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Research 57: 4183–4186.PubMedGoogle Scholar
  184. Wang, H., W. Zhang, H.J. Huang, W.S. Liao, and G.N. Fuller. 2004. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Laboratory Investigation 84: 941–951.PubMedCrossRefGoogle Scholar
  185. Ward, P.S., J. Patel, D.R. Wise, et al. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225–234.PubMedPubMedCentralCrossRefGoogle Scholar
  186. Watanabe, K., O. Tachibana, K. Sata, Y. Yonekawa, P. Kleihues, and H. Ohgaki. 1996. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathology 6: 217–223; discussion 223–214.PubMedCrossRefGoogle Scholar
  187. Watanabe, T., S. Nobusawa, P. Kleihues, and H. Ohgaki. 2009. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. The American Journal of Pathology 174: 1149–1153.PubMedPubMedCentralCrossRefGoogle Scholar
  188. Weller, M., J. Felsberg, C. Hartmann, et al. 2009. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. Journal of Clinical Oncology 27: 5743–5750.PubMedCrossRefGoogle Scholar
  189. Wen, P.Y., W.K. Yung, K.R. Lamborn, et al. 2006. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research 12: 4899–4907.PubMedCrossRefGoogle Scholar
  190. Wen, P.Y.P.M., D. Schiff, D.A. Reardon, T. Cloughesy, T. Mikkelsen, T. Batchelor, J. Drappatz, M.C. Chamberlain, and J.F. De Groot. 2010. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) [abstract]. Journal of Clinical Oncology 28: 181s.CrossRefGoogle Scholar
  191. Wick, W., V.K. Puduvalli, M.C. Chamberlain, et al. 2010. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Journal of Clinical Oncology 28: 1168–1174.PubMedPubMedCentralCrossRefGoogle Scholar
  192. Wick, W., J.P. Steinbach, M. Platten, et al. 2013. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology 15: 1405–1412.PubMedPubMedCentralCrossRefGoogle Scholar
  193. Wong, A.J., J.M. Ruppert, S.H. Bigner, et al. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America 89: 2965–2969.PubMedPubMedCentralCrossRefGoogle Scholar
  194. Yan, H., D.W. Parsons, G. Jin, et al. 2009. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 360: 765–773.PubMedPubMedCentralCrossRefGoogle Scholar
  195. Yung, W.K., J.J. Vredenburgh, T.F. Cloughesy, et al. 2010. Safety and efficacy of erlotinib in first-relapse glioblastoma: A phase II open-label study. Neuro-Oncology 12: 1061–1070.PubMedPubMedCentralCrossRefGoogle Scholar
  196. Yust-Katz, S., D. Liu, Y. Yuan, et al. 2013. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119: 2747–2753.PubMedPubMedCentralCrossRefGoogle Scholar
  197. Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.PubMedCrossRefGoogle Scholar
  198. Zhu, Y., F. Guignard, D. Zhao, et al. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8: 119–130.PubMedPubMedCentralCrossRefGoogle Scholar
  199. Zwick, E., J. Bange, and A. Ullrich. 2001. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocrine-Related Cancer 8: 161–173.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Michael Youssef
    • 1
  • Jacob Mandel
    • 2
  • Sajeel Chowdhary
    • 3
  • Santosh Kesari
    • 4
  1. 1.Department of Neurology at Baylor College of MedicineHoustonUSA
  2. 2.Neurology and Neurosurgery at Baylor College of MedicineHoustonUSA
  3. 3.Lynn Cancer Institute, Marcus Neuroscience InstituteBoca RatonUSA
  4. 4.Department of Translational Neurosciences and NeurotherapeuticsJohn Wayne Cancer Institute and Pacific Neuroscience Institute at Providence Saint John’s Health CenterSanta MonicaUSA

Personalised recommendations